# 324 — Final engineering handoff

**CR:** `CR-324-FINAL-ENGINEERING-HANDOFF`  
**Updated:** 31 August 2026 (awaiting next authorization — engineering loop stopped)  
**Type:** Documentation / stakeholder handoff only — **no product code, migrations, config, or implementation**  
**Verdict:** **`WORLD_PHARMA_ENGINEERING_PAUSE — AWAITING_NEXT_AUTHORIZATION`**

Also recorded:

- **`WORLD_PHARMA_SANDBOX_ENGINEERING_COMPLETE`**
- **`NO_AUTHORIZED_UNBLOCKED_ENGINEERING_WORK`**
- **`HANDOFF_COMPLETE`** (prior close; superseded as current wait state by this update)

**Owner fill surface (R14-A):** [R14_A_OWNER_GATE_CHECKLIST.md](R14_A_OWNER_GATE_CHECKLIST.md) (**0/7 production evidence**)  
**Engineering config store:** [326](326_R14_A_ENGINEERING_CONFIG.md) — **`R14_A_ENGINEERING_CONFIG_READY`** with DEV placeholders and Main Admin provider catalog on existing `payment_gateways`; **not** live-ready  
**Canonical gates:** [263](263_R14_A_HUMAN_APPROVAL_HANDOFF.md) · evidence log [247](247_R14_A_HUMAN_GATE_EVIDENCE.md)

This book does **not** authorize R14-A live PSP, live eRx, production video, live carrier, live payout, R15, or R16. **CR-R14-A-IMPL-244 stays closed.** `PAYMENT_LIVE_ENABLED` is not changed.

---

## 0. Purpose

World-Pharma engineering is **paused awaiting authorization**. Do not run another generic ecosystem audit. Do not create another CR. Do not invent features. Do not modify completed sandbox tracks.

The next action is **PATH A** (real R14-A owner evidence) or **PATH B** (explicit Product IMPL authorization). A generic request to “continue development” is **not** PATH B.

---

## 1. What is complete (do not reopen)

| Area | Status | Notes |
| ---- | ------ | ----- |
| R0–R13 sandbox kernels | **COMPLETE** | Book [93](93_GLOBAL_IMPLEMENTATION_ROADMAP.md) closed waves |
| R14-A sandbox payment kernel | **COMPLETE** | [280](280_R14_A_FINAL_CODE_AUDIT.md) — live rails off |
| R14-B sandbox finance | **COMPLETE** | [292](292_R14_POST_R14B_CLOSURE_VERIFICATION.md) |
| CR-304 through CR-323 | **COMPLETE** | Search index, schedulers, notifications, SUPERSEDE, pause audit |
| Lab/imaging Health artifact SUPERSEDE | **COMPLETE** | `HealthDiagnosticProjectionService` (CR-322) |
| Notification recipient parity | **COMPLETE** | CR-309, 313, 315–321 |
| CRM automation scheduler | **COMPLETE** | CR-310 |
| Campaign auto-send | **COMPLETE** | CR-311 |
| Abandoned-cart recovery | **COMPLETE** | CR-312 |
| Search / index / analytics slices already implemented | **COMPLETE** | CR-304, 305, 306 |

Authorized + unblocked REAL_DEFECT / REAL_MISSING_FEATURE: **ZERO**.

---

## 2. What remains human-blocked

### 2.1 R14-A live PSP — readiness **0/7**

Do not implement live PSP until genuine **7/7** evidence exists. Fill [R14_A_OWNER_GATE_CHECKLIST.md](R14_A_OWNER_GATE_CHECKLIST.md). Never commit secrets.

| # | Gate | Exact owner evidence required | Status |
| - | ---- | ----------------------------- | ------ |
| 1 | Named PSP | Approved PSP name; decision authority; decision date; memo/decision reference | **NOT_EVIDENCED** |
| 2 | First production country | Real ISO2 (not `XX`/`TQ`); approval authority; approval date; approval reference | **NOT_EVIDENCED** |
| 3 | Legal entity | Contracting entity name; jurisdiction; legal approval reference | **NOT_EVIDENCED** |
| 4 | Merchant of Record | `platform MoR` / `facilitator` / `vendor-as-seller`; responsible entity; OD-PAY-01 decision reference | **NOT_EVIDENCED** |
| 5 | PSP contract ID | Signed contract ID/reference only (not the PDF in git) | **NOT_EVIDENCED** |
| 6 | Production vault path | Secret-manager **path/reference only** (never keys, PAN, CVV, certs) | **NOT_EVIDENCED** |
| 7 | PCI SAQ / attestation | Applicable SAQ type; attestation/reference ID (not `pci.spec.ts` or “No PAN/CVV”) | **NOT_EVIDENCED** |

**After 7/7:** do **not** enable `PAYMENT_LIVE_ENABLED` and do **not** execute CR-244. Return `R14_A_7_OF_7_EVIDENCED — FRESH_IMPLEMENTATION_AUDIT_REQUIRED`, then a **new** live-PSP scope CR.

### 2.2 R4 production video

| Required | Owner |
| -------- | ----- |
| Named SFU/provider (OD-VID-01) | Product + Legal |
| Production credentials (not in git) | Ops |
| Teleconsult licensing / operational go-live | Legal + Ops |
| Recording consent if ever enabled (currently off) | Legal |

Sandbox: `MockVideoProvider` default.

### 2.3 R5-F live eRx

| Required | Owner |
| -------- | ----- |
| Named live eRx provider adapter | Product + Legal |
| Credentials/certificates (not in git) | Ops + provider |
| L-RX-01 / pack enablement | Legal + Clinical ops |
| Explicit IMPL CR after those gates | Product |

Sandbox: `SandboxERxAdapter` only (`ERX_PROVIDER=sandbox`). **OD-RX-REFILL** unresolved — auto-refill stays OFF.

### 2.4 Live carrier / payout

| Required | Owner |
| -------- | ----- |
| Carrier contract, credentials, coverage | Logistics + Legal |
| Regulated-shipping review, live pricing, actual-cost recon | Logistics + Finance |
| Named payout provider + credentials | Finance |
| Operational approval to leave sandbox | Business |

Sandbox: mock `executeBooking`; R14-B sandbox payout ledger.

---

## 3. What remains deferred

Until Product issues a **specific implementation authorization/CR**:

| Item | Why deferred |
| ---- | ------------ |
| **R15** control-plane / DR (workforce, maker-checker, flags, residency, DR evidence) | Book 93 **LATER**; no R15 IMPL book |
| **R16** second country / optional extract | Book 93 **LATER**; OD-COUNTRY-01 open; packs not forks |
| TD-R12B-07 cancel-campaign API | R12 closed; Book 221 no new R12 scope |
| LogisticsWorker async producers | Unused scaffold; sync booking works; live carrier is R14 |
| R9-X redaction / legal hold / caregiver consent | Book 170 DEFERRED |
| Wallet | Country-gated; not sandbox completeness |
| OpenSearch | R13 Postgres-first |
| Lab-staff RN | Book 93 PLANNED |
| Affiliate mobile | Never unless a future CR |
| DICOM/PACS | R8 sandbox pointers only |
| Optional consult-note capture UI | R10-F API complete |
| External push / SMS / email / WhatsApp | One kernel; adapters; packs default off |
| Generic Partner App | Forbidden |
| Auto-refill | OD-RX-REFILL unresolved |

---

## 4. Two valid paths (only)

Until PATH A has real evidence or PATH B has explicit authorization: **no product code, migrations, live SDKs, production flags, speculative fixes, cosmetic work, or CR numbering.**

### PATH A — R14-A production readiness

Track [R14_A_OWNER_GATE_CHECKLIST.md](R14_A_OWNER_GATE_CHECKLIST.md). Current: **0/7 — NOT_EVIDENCED**. Do not fabricate or infer values.

When genuine owner evidence is supplied: **one** Book 263 reconciliation. If **7/7**: `R14_A_7_OF_7_EVIDENCED — FRESH_IMPLEMENTATION_AUDIT_REQUIRED`. **Do not execute CR-244.** Then a **new** live-PSP implementation authorization.

### PATH B — New authorized roadmap wave

Product must issue an implementation authorization that names **all** of: track (R15 / R16 / deferred item), exact requirement, scope, acceptance criteria, authorization/CR reference, any human dependencies.

Do **not** treat “continue development” as PATH B.

A newly proven **requirement-level defect** (source + roadmap) is also a valid engineering trigger; it is not a substitute for PATH A/B live-integration work.

---

## 5. Migration / runtime / test baseline

Last verified 31 August 2026 (CR-322 e2e / CR-324 handoff). **This update does not re-run typecheck, build, or migrate.**

| Surface | Result | Meaning |
| ------- | ------ | ------- |
| E2E DB `worldpharma_test` | **149/149**, 0 pending | Engineering-complete **test** environment |
| Host/dev DB `worldpharma` | **7 pending** (`r10e`, `r10f`, `r5f`, `r12b`) | Environment drift — **do not apply** as a production gesture |
| `GET /health/ready` | ready (postgres/redis/bullmq) at last check | Local runtime |
| `npx nx run api:typecheck` | PASS (last check) | Sandbox compile |
| `npx nx build api` | PASS (last check) | Sandbox bundle |

Engineering-complete test environment ≠ production readiness.

---

## 6. Security / safety (unchanged; no new controls)

| Control | Contract |
| ------- | -------- |
| FORCE RLS | Tenant tables; app role `worldpharma_app` ([97](97_MULTI_TENANT_RLS_RETROFIT_IMPLEMENTATION.md)) |
| Tenant isolation | `runWithTenant` GUCs |
| JWT / audience RBAC | Membership scope; UI hide ≠ authz |
| Outbox / inbox idempotency | `occurrenceKey`; `EventWorkerService` |
| Payment fail-closed | `PAYMENT_LIVE_ENABLED` not true by default |
| Live eRx fail-closed | Only `ERX_PROVIDER=sandbox` |
| Production video | Mock unless LiveKit triple is set |
| Clinical search fail-closed | OD-R13-04 |

PAN/CVV must never land on platform. Partners must never receive `company_*`.

---

## 7. Explicit statement

**`NO_AUTHORIZED_UNBLOCKED_ENGINEERING_WORK`**

---

## 8. Final verdict

**`WORLD_PHARMA_ENGINEERING_PAUSE — AWAITING_NEXT_AUTHORIZATION`**
